![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual functio... Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual function primarily by reducing the macular edema associated with several diseases affecting vision. Show more
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - Robust Safety Profile and Encouraging Efficacy Data Reported Utilizing SCS Microinjector® - ALPHARETTA...
- Expert Panel of Ophthalmologists Developed Professional Guidelines in Using the Innovative Technique for Retinal Therapeutic Delivery - - Current Clinical Evidence and Physician Experience...
- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected Q3 2024 - - Strengthened Management Team and Board of Directors with Two Key Additions -- Management to Host...
ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye...
ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye...
ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye...
ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.15 | -12.1951219512 | 1.23 | 1.24 | 1.06 | 185854 | 1.15162517 | CS |
4 | -0.29 | -21.1678832117 | 1.37 | 1.45 | 1.06 | 144428 | 1.2417062 | CS |
12 | -0.44 | -28.9473684211 | 1.52 | 1.6288 | 1.06 | 212714 | 1.31362477 | CS |
26 | 0.02 | 1.88679245283 | 1.06 | 2.12 | 1 | 283254 | 1.46075882 | CS |
52 | -0.22 | -16.9230769231 | 1.3 | 2.12 | 0.650101 | 206354 | 1.3128851 | CS |
156 | -3.64 | -77.1186440678 | 4.72 | 7.73 | 0.650101 | 371987 | 2.91437098 | CS |
260 | 0.02 | 1.88679245283 | 1.06 | 7.73 | 0.56 | 581207 | 2.84638732 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions